Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

XDEMVY is indicated for the treatment of Demodex blepharitis. Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects ...

Tarsus Pharmaceuticals (TARS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

A pharmacist has warned that allergy sufferers could be in for a difficult time this autumn and winter. Allergies affecting ...

TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second ...

I've had a genital itch for years. I take prescription drugs which have itchiness listed as a side effect, but I can't ...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new ...

This clear documentation will guide the clinician in comparing previous to subsequent TVDs in the same patient and may aid in the assessment of the efficacy of the treatment modalities administered.

Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

“Such eye conditions like red eye (conjunctivitis), blepharitis or a stye, require immediate treatment to prevent them getting worse. Here I would recommend GoldenEye Eye Ointment or GoldenEye ...

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialed by clinicians and ...